Trinity Biotech (TRIB) EBIT Margin (2009 - 2024)

Trinity Biotech has disclosed EBIT Margin across 16 years of filings, most recently posting 72.61% for Q4 2024.

• EBIT Margin for Q4 2024 came in at 72.61%, down 4446.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 34.38% (up 1321.0% YoY), and the FY2025 annual result was 36.06%, down 168.0% from the prior year.
• EBIT Margin came in at 72.61% for Q4 2024 at Trinity Biotech, down from 16.88% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 28.38% in Q3 2020 to a low of 106.86% in Q2 2023.
• The 5-year median for EBIT Margin is 14.44% (2022), against an average of 17.79%.
• Across the five-year window, EBIT Margin sank 9486 bps in 2023 and surged 8129 bps in 2024, its largest moves.
• Trinity Biotech's EBIT Margin stood at 27.67% in 2020, then tumbled by 90 bps to 2.88% in 2021, then slumped by 1899 bps to 51.87% in 2022, then jumped by 46 bps to 28.14% in 2023, then sank by 158 bps to 72.61% in 2024.
• The last three EBIT Margin figures came in at 72.61% (Q4 2024), 16.88% (Q3 2024), and 25.58% (Q2 2024), per Business Quant data.